	US 11,873,338 B2
	CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease
Alexander Berthold Hendrik Bakker, Utrecht (NL); Cornelis Jacob Johannes George Bol, Utrecht (NL); Pieter Fokko Van Loo, Utrecht (NL); Leonardo Andres Sirulnik, Utrecht (NL); and Ernesto Isaac Wasserman, Utrecht (NL)
Assigned to Merus N.V., Utrecht (NL)
Appl. No. 17/294,338
Filed by Merus N.V., Utrecht (NL)
PCT Filed Dec. 20, 2019, PCT No. PCT/NL2019/050864 § 371(c)(1), (2) Date May 14, 2021, PCT Pub. No. WO2020/130829, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 18214478 (EP), filed on Dec. 20, 2018.
Prior Publication US 2022/0010013 A1, Jan. 13, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 35/28 (2015.01); A61K 39/00 (2006.01)

CPC C07K 16/2809 (2013.01) [A61K 35/28 (2013.01); A61P 35/00 (2018.01); C07K 16/2851 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01); C07K 2317/73 (2013.01); C07K 2317/74 (2013.01); C07K 2317/92 (2013.01)]

13 Claims

1. A method of treating a subject for a CLEC12A positive cancer, the method comprising treating the subject in need thereof with two or more administrations of a bispecific antibody that binds CD3 and CLEC12A, wherein in a first administration a first amount of the bispecific antibody is administered and wherein in subsequent administrations the amount of bispecific antibody is higher than the amount of bispecific antibody in the first administration, wherein the first administration is a subtherapeutic amount of bispecific antibody.